Bosutinib
Product Specifications
UNSPSC Description
Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively[1].
Target Antigen
Autophagy; Bcr-Abl; Src
Type
Reference compound
Related Pathways
Autophagy;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Bosutinib.html
Purity
99.96
Solubility
DMSO : ≥ 46 mg/mL
Smiles
CN1CCN(CC1)CCCOC2=C(C=C3C(NC4=CC(OC)=C(C=C4Cl)Cl)=C(C=NC3=C2)C#N)OC
Molecular Weight
530.45
References & Citations
[1]Jorge E Cortes, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012 Oct 1;30(28):3486-92.|[2]Miriam Puttini, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006 Dec 1;66(23):11314-22.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-10158/Bosutinib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-10158/Bosutinib-SDS-MedChemExpress.pdf
Clinical Information
Launched
CAS Number
380843-75-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
BNC882375-100 100 µL
Anti-Cytokeratin 14 (KRT14) (Squamous Cell Marker)(KRT14/2375), CF488A conjugate
Ask
View Details 